United States Food and Drug Administration (USFDA) has successfully completed an unannounced inspection at Rubicon Research’s R&D facility located at Concord, Ontario, Canada, from April 20, 2026 to April 24, 2026. The inspection concluded without any Form-483 being issued.
Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of speciality products and drug-device combination products targeting regulated markets and in particular the United States.
